Skip to main content

Articles

26 result(s) for 'Lecanemab' within Alzheimer's Research & Therapy

Page 1 of 1

  1. Authors: Chad J. Swanson, Yong Zhang, Shobha Dhadda, Jinping Wang, June Kaplow, Robert Y. K. Lai, Lars Lannfelt, Heather Bradley, Martin Rabe, Akihiko Koyama, Larisa Reyderman, Donald A. Berry, Scott Berry, Robert Gordon, Lynn D. Kramer and Jeffrey L. Cummings
    Citation: Alzheimer's Research & Therapy 2022 14:70

    The original article was published in Alzheimer's Research & Therapy 2021 13:80

  2. Lecanemab (BAN2401) is a humanized IgG1 monoclonal ... this trial, subjects were randomized to five lecanemab dose regimens or placebo. The primary efficacy ... of sensitivity analyses evaluating the consistency ...

    Authors: Shobha Dhadda, Michio Kanekiyo, David Li, Chad J. Swanson, Michael Irizarry, Scott Berry, Lynn D. Kramer and Donald A. Berry
    Citation: Alzheimer's Research & Therapy 2022 14:182
  3. Lecanemab (BAN2401), an IgG1 monoclonal antibody, ... to assess 3 doses across 2 regimens of lecanemab versus placebo in early Alzheimer’s disease,...

    Authors: Chad J. Swanson, Yong Zhang, Shobha Dhadda, Jinping Wang, June Kaplow, Robert Y. K. Lai, Lars Lannfelt, Heather Bradley, Martin Rabe, Akihiko Koyama, Larisa Reyderman, Donald A. Berry, Scott Berry, Robert Gordon, Lynn D. Kramer and Jeffrey L. Cummings
    Citation: Alzheimer's Research & Therapy 2021 13:80

    The Correction to this article has been published in Alzheimer's Research & Therapy 2022 14:70

  4. Lecanemab, a humanized IgG1 monoclonal antibody that targets ... core and OLE) supporting the effectiveness of lecanemab.

    Authors: Eric McDade, Jeffrey L. Cummings, Shobha Dhadda, Chad J. Swanson, Larisa Reyderman, Michio Kanekiyo, Akihiko Koyama, Michael Irizarry, Lynn D. Kramer and Randall J. Bateman
    Citation: Alzheimer's Research & Therapy 2022 14:191
  5. In Alzheimer’s disease (AD), amyloid-β 1–42 (Aβ42) neurotoxicity stems mostly from its soluble oligomeric aggregates. Studies of such aggregates have been hampered by the lack of oligomer-specific research too...

    Authors: Anders Sandberg, Ernesto Berenjeno-Correa, Rosa Crespo Rodriguez, Michael Axenhus, Sophia Schedin Weiss, Kevin Batenburg, Jeroen J. M. Hoozemans, Lars O. Tjernberg and Wiep Scheper
    Citation: Alzheimer's Research & Therapy 2022 14:196
  6. Brain-directed immunotherapy is a promising strategy to target amyloid-β (Aβ) deposits in Alzheimer’s disease (AD). In the present study, we compared the therapeutic efficacy of the Aβ protofibril targeting an...

    Authors: Tobias Gustavsson, Nicole G. Metzendorf, Elin Wik, Sahar Roshanbin, Ulrika Julku, Aikaterini Chourlia, Per Nilsson, Ken G. Andersson, Hanna Laudon, Greta Hultqvist, Stina Syvänen and Dag Sehlin
    Citation: Alzheimer's Research & Therapy 2023 15:90
  7. The development of drugs for Alzheimer’s disease (AD), which is related to the misfolding and aggregation of amyloid-β (Aβ), is high in demand due to the growing number of AD patients. In this study, we screen...

    Authors: Rina Nakamura, Motomi Konishi, Youichirou Higashi, Motoaki Saito and Toshifumi Akizawa
    Citation: Alzheimer's Research & Therapy 2023 15:83
  8. With the emergence of disease-modifying Alzheimer’s treatments, timely detection of early-stage disease is more important than ever, as the treatment will not be indicated for later stages. Contemporary popula...

    Authors: Soeren Mattke, Hankyung Jun, Emily Chen, Ying Liu, Andrew Becker and Christopher Wallick
    Citation: Alzheimer's Research & Therapy 2023 15:128
  9. Alzheimer’s disease (AD) is a major global health crisis in need of more effective therapies. However, difficult choices to optimize value-based care will need to be made. While identifying preferred therapeut...

    Authors: George Dranitsaris, Quanwu Zhang, Lin Mu, Christopher Weyrer, Erik Drysdale, Peter Neumann, Alireza Atri and Amir Abbas Tahami Monfared
    Citation: Alzheimer's Research & Therapy 2023 15:60
  10. The mismatch between the limited availability versus the high demand of participants who are in the pre-dementia phase of Alzheimer’s disease (AD) is a bottleneck for clinical studies in AD. Nevertheless, pote...

    Authors: Ilse Bader, Ilona Bader, Isadora Lopes Alves, David Vállez García, Bruno Vellas, Bruno Dubois, Mercè Boada, Marta Marquié, Daniele Altomare, Philip Scheltens, Rik Vandenberghe, Bernard Hanseeuw, Michael Schöll, Giovanni B. Frisoni, Frank Jessen, Agneta Nordberg…
    Citation: Alzheimer's Research & Therapy 2023 15:189
  11. Current treatments for Alzheimer’s disease (AD) have largely failed to yield significant therapeutic benefits. Novel approaches are desperately needed to help address this immense public health issue. Data sug...

    Authors: Nancy R. Stallings, Melissa A. O’Neal, Jie Hu, Zhong-Jian Shen and James S. Malter
    Citation: Alzheimer's Research & Therapy 2023 15:179
  12. This review describes the research and development process of gantenerumab, a fully human anti-amyloid monoclonal antibody in development to treat early symptomatic and asymptomatic Alzheimer’s disease (AD). A...

    Authors: Randall J. Bateman, Jeffrey Cummings, Scott Schobel, Stephen Salloway, Bruno Vellas, Mercè Boada, Sandra E. Black, Kaj Blennow, Paulo Fontoura, Gregory Klein, Sheila Seleri Assunção, Janice Smith and Rachelle S. Doody
    Citation: Alzheimer's Research & Therapy 2022 14:178
  13. The glymphatic system is a crucial component in preserving brain homeostasis by facilitating waste clearance from the central nervous system (CNS). Aquaporin-4 (AQP4) water channels facilitate the continuous i...

    Authors: Pablo Mohaupt, Jérôme Vialaret, Christophe Hirtz and Sylvain Lehmann
    Citation: Alzheimer's Research & Therapy 2023 15:170
  14. Patient stratification is the division of a patient population into distinct subgroups based on the presence or absence of particular disease characteristics. As patient stratification can be used to account f...

    Authors: Carla Abdelnour, Federica Agosta, Marco Bozzali, Bertrand Fougère, Atsushi Iwata, Ramin Nilforooshan, Leonel T. Takada, Félix Viñuela and Martin Traber
    Citation: Alzheimer's Research & Therapy 2022 14:112
  15. To enable successful inclusion of electroencephalography (EEG) outcome measures in Alzheimer’s disease (AD) clinical trials, we retrospectively mapped the progression of resting-state EEG measures over time in...

    Authors: Elliz P. Scheijbeler, Willem de Haan, Cornelis J. Stam, Jos W. R. Twisk and Alida A. Gouw
    Citation: Alzheimer's Research & Therapy 2023 15:182
  16. Recruiting to multi-site trials is challenging, particularly when striving to ensure the randomized sample is demographically representative of the larger disease-suffering population. While previous studies h...

    Authors: Dylan R. Kirn, Joshua D. Grill, Paul Aisen, Karin Ernstrom, Seth Gale, Judith Heidebrink, Gregory Jicha, Gustavo Jimenez-Maggiora, Leigh Johnson, Elaine Peskind, Kelly McCann, Elizabeth Shaffer, David Sultzer, Shunran Wang, Reisa Sperling and Rema Raman
    Citation: Alzheimer's Research & Therapy 2023 15:88
  17. Alzheimer’s disease (AD) is an age-related disease characterized by altered cognition, neuroinflammation, and neurodegeneration against which there is presently no effective cure. Brain-derived neurotrophic fa...

    Authors: Simone Tambaro, Sumonto Mitra, Ruchi Gera, Bengt Linderoth, Lars U. Wahlberg, Taher Darreh-Shori, Homira Behbahani, Per Nilsson and Maria Eriksdotter
    Citation: Alzheimer's Research & Therapy 2023 15:137
  18. To estimate the perceived value of additional testing with amyloid-PET in Euros in healthy participants acting as analogue patients with mild cognitive impairment (MCI).

    Authors: I. S. van Maurik, E. D. Bakker, A. A. J. M. van Unnik, H. M. Broulikova, M. D. Zwan, E. van de Giessen, J. Berkhof, F. H. Bouwman, J. E. Bosmans and W. M. van der Flier
    Citation: Alzheimer's Research & Therapy 2023 15:208
  19. Key points of disagreement between the aducanumab FDA statistical review, which had primarily negative conclusions, and the clinical review, which had primarily positive conclusions, were investigated. Results...

    Authors: Samuel P. Dickson, Sean Hennessey, Jessie Nicodemus Johnson, Newman Knowlton and Suzanne B. Hendrix
    Citation: Alzheimer's Research & Therapy 2023 15:98
  20. Gamma (γ) brain oscillations are dysregulated in Alzheimer’s disease (AD) and can be modulated using transcranial alternating stimulation (tACS). In the present paper, we describe the rationale and design of a...

    Authors: Daniele Altomare, Alberto Benussi, Valentina Cantoni, Enrico Premi, Jasmine Rivolta, Chiara Cupidi, Alessandro Martorana, Emiliano Santarnecchi, Alessandro Padovani, Giacomo Koch and Barbara Borroni
    Citation: Alzheimer's Research & Therapy 2023 15:155
  21. Hyperhomocysteinemia (HHcy) has been linked to development of Alzheimer’s disease (AD) neuropathologically characterized by the accumulation of amyloid β (Aβ). Microglia (MG) play a crucial role in uptake of A...

    Authors: Xianwei Wang, Lu Liu, Xiaohua Jiang, Jason Saredy, Hang Xi, Ramon Cueto, Danni Sigler, Mohsin Khan, Sheng Wu, Yong Ji, Nathaniel W. Snyder, Wenhui Hu, Xiaofeng Yang and Hong Wang
    Citation: Alzheimer's Research & Therapy 2023 15:164
  22. Aggregation of the amyloid-β (Aβ) peptide in the brain is one of the key pathological events in Alzheimer’s disease (AD). Reducing Aβ levels in the brain by enhancing its degradation is one possible strategy t...

    Authors: Fadi Rofo, Nicole G. Metzendorf, Cristina Saubi, Laura Suominen, Ana Godec, Dag Sehlin, Stina Syvänen and Greta Hultqvist
    Citation: Alzheimer's Research & Therapy 2022 14:180
  23. Tauopathies are a group of neurodegenerative disorders characterized by the aggregation of the microtubule-associated protein tau. Aggregates of misfolded tau protein are believed to be implicated in neuronal ...

    Authors: Jeffrey L. Cummings, M. Isabel Gonzalez, Martyn C. Pritchard, Patrick C. May, Leticia M. Toledo-Sherman and Glenn A. Harris
    Citation: Alzheimer's Research & Therapy 2023 15:168